Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

28 Aug 2020 15:27

RNS Number : 5084X
Collagen Solutions PLC
28 August 2020
 

Collagen Solutions plc

(the "Company")

 

Director/PDMR Dealing

 

1. Vesting / exercise of Deferred Bonus Awards granted in October 2019

 

Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that, on 28 August 2020, the executive director and other persons discharging managerial responsibility ("PDMRs") set out in the table below acquired ordinary shares of 1 pence each in the share capital of the Company ("Shares") pursuant to the vesting / exercise of awards originally granted under the Collagen Solutions plc Deferred Bonus Plan on 2 October 2019 (the "Awards"). No consideration was payable for these Shares.

 

Director/PDMR

Position

Number of Shares acquired on 28 August 2020

Jamal Rushdy

Chief Executive Officer

906,145

Lou Ruggiero

Chief Business Officer

806,559

Brad Selman

PDMR / VP Global Sales and Marketing

284,202

Chris Wattengel

PDMR / VP Global R&D

246,514

Kevin Darling

PDMR / VP Tissue Products

173,596

 

Notes:

1 A number of other individuals, including Hilary Spence, Chief Financial Officer, were also granted Awards under the Deferred Bonus Plan on 2 October 2019. Although these Awards (which are in the form of "nil-cost" options) have now vested, the relevant holders have not yet elected to exercise their rights and acquire their Shares.

 

The Shares required to satisfy the above vestings / exercises were transferred to the relevant individuals by the trustee of the Collagen Solutions plc Employee Benefit Trust (the "EBT"). As previously announced, these Shares were allotted to the EBT on 11 August 2020.

 

2. Total beneficial holdings in the Company

 

Following the above notifications, the total holdings of Shares of the relevant PDMRs are as follows:

 

Director/PDMR

Position

Total holding following this notification

Approximate % of the Company's issued share capital

Jamal Rushdy

Chief Executive Officer

1,906,145

0.43%

Lou Ruggiero

Chief Business Officer

806,559

0.18%

Brad Selman

PDMR / VP Global Sales and Marketing

284,202

0.06%

Chris Wattengel

PDMR / VP Global R&D

246,514

0.06%

Kevin Darling

PDMR / VP Tissue Products

173,596

0.04%

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

1. Jamal Rushdy

2. Lou Ruggiero

3. Brad Selman

4. Chris Wattengel

5. Kevin Darling

2

Reason for the notification

a)

Position/status

1. Chief Executive Officer

2. Chief Business Officer

3. PDMR / VP Global Sales and Marketing

4. PDMR / VP Global R&D

5. PDMR / VP Tissue Products

b)

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Collagen Solutions plc

b)

LEI

213800IFY1CVGRGETL95

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of 1p each ("Shares")

Identification code

ISIN Code: GB00B94T6Y14

b)

Nature of the transaction

Acquisition of Shares on the vesting / exercise of Awards originally granted on 2 October 2019 pursuant to the Collagen Solutions plc Deferred Bonus Plan

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

1.

nil

906,145

2.

nil

806,559

3.

nil

284,202

4.

nil

246,514

5.

nil

173,596

d)

Aggregated information

- Aggregated volume

- Price

1. N/A single transaction

2. N/A single transaction

3. N/A single transaction

4. N/A single transaction

5. N/A single transaction

e)

Date of the transaction

2020-08-28

f)

Place of the transaction

Outside a trading venue

 

Enquiries:

Collagen Solutions Plc

Jamal Rushdy, CEO

 

Hilary Spence, CFO

Via Walbrook

Cenkos Securities Plc (Nominated Adviser and Broker)

Giles Balleny (Corporate Finance)

Tel: 0207 397 8900

Stephen Keys

Walbrook PR Ltd

Tel: 020 7933 8780 or collagen@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHKKFBBQBKDPFB
Date   Source Headline
12th Sep 20167:00 amRNSIssue of Equity
24th Aug 201611:26 amRNSResult of AGM
25th Jul 201611:48 amRNSPosting of Annual Report
19th Jul 20167:15 amRNSHardman research: Focused scalable growth
15th Jul 20167:00 amRNSGrant of Options
12th Jul 20165:12 pmRNSDirector/PDMR Shareholding
12th Jul 201611:51 amRNSHolding(s) in Company
11th Jul 20164:15 pmRNSDirector/PDMR Shareholding
11th Jul 20163:16 pmRNSDirector/PDMR Shareholding
11th Jul 20167:00 amRNSFinal Results
13th Jun 20167:00 amRNSNotice of Results Investor Presentation
4th May 20167:00 amRNSDirectorate Change
3rd May 20167:00 amRNSLeadership changes and preliminary FY revenue
27th Apr 20165:34 pmRNSHolding(s) in Company
26th Apr 20168:28 amRNSJoint Venture Agreement in China
19th Apr 20167:00 amRNSSupply of collagen materials to Merck
30th Mar 20169:37 amRNSHolding(s) in Company
23rd Mar 20167:00 amRNSResearch collaboration
26th Feb 20161:02 pmRNSHolding(s) in Company
12th Feb 20167:00 amRNSDeath of adviser
3rd Feb 20167:00 amRNSCollagen Solutions present at The Scotsman
22nd Jan 20165:47 pmRNSHolding(s) in Company
21st Jan 201610:14 amRNSChairman's Share Purchase
20th Jan 20167:00 amRNSTrading Update
14th Jan 20165:29 pmRNSHolding(s) in Company
9th Dec 201511:17 amRNSHolding(s) in Company
9th Dec 20157:00 amRNSHardman Issues Research Report
7th Dec 20157:00 amRNSCollagen Solutions Supply Agreement with BBI
2nd Dec 20153:48 pmRNSDirector/PDMR Shareholding
1st Dec 20157:00 amRNSHalf Yearly Report
20th Nov 20153:20 pmRNSDeath of a Director
18th Nov 20157:00 amRNSAppointment of Chief Business Officer
3rd Nov 20157:00 amRNSNotice of Results
28th Sep 20157:00 amRNSCollagen supply agreement to Yucel Medical
22nd Sep 20157:00 amRNSMedical Research Studentship
16th Sep 20157:00 amRNSSupply Agreement with Histogenics Corporation
14th Sep 20157:00 amRNSAcquisition of a regenerative medicine product
3rd Sep 20157:00 amRNSFDA approval for NovaBone product
28th Aug 201510:11 amRNSAGM Statement
28th Aug 20157:00 amRNSJoins consortium developing new treatments
22nd Jul 20157:00 amRNSPosting of Annual Report & Notice of AGM
15th Jul 201510:09 amRNSHardman & Co issues research on Collagen Solutions
14th Jul 20157:00 amRNSPartnership with UCL and Oxford MEStar Ltd
13th Jul 20157:00 amRNSFinal Results
3rd Jul 20152:11 pmRNSNotice of Results
26th Jun 20157:00 amRNSChange of Adviser
22nd Jun 20157:00 amRNSInnovate UK Grant Award
28th May 20157:00 amRNSNew Patent Granted
17th Apr 20151:53 pmRNSHardman & Co issues research report
14th Apr 20157:00 amRNSUK Investor Show attendance

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.